NDC 0143-9642 Zoledronic Acid
Injection, Solution, Concentrate Intravenous
NDC Code 0143-9642-01
Package Description: 5 mL in 1 VIAL
What is NDC 0143-9642?
The NDC code 0143-9642 is assigned by the FDA to the product Zoledronic Acid which is a human prescription drug product labeled by Hikma Pharmaceuticals Usa Inc.. The product's dosage form is injection, solution, concentrate and is administered via intravenous form. The product is distributed in a single package with assigned NDC code 0143-9642-01 5 ml in 1 vial . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.
What are the uses for Zoledronic Acid?
This medication is used to treat high blood calcium levels (hypercalcemia) that may occur with cancer. Zoledronic acid is also used with cancer chemotherapy to treat bone problems that may occur with multiple myeloma and other types of cancer (such as breast, lung) that have spread to the bones. Zoledronic acid belongs to a class of drugs known as bisphosphonates. It lowers high blood calcium levels by reducing the amount of calcium released from your bones into your blood. It also works by slowing the breakdown of your bones by cancer to prevent bone fractures.
What are Zoledronic Acid Active Ingredients?
An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
- ZOLEDRONIC ACID 4 mg/5mL - An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.
Which are Zoledronic Acid UNII Codes?
The UNII codes for the active ingredients in this product are:
- ZOLEDRONIC ACID (UNII: 6XC1PAD3KF)
- ZOLEDRONIC ACID ANHYDROUS (UNII: 70HZ18PH24) (Active Moiety)
Which are Zoledronic Acid Inactive Ingredients UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MANNITOL (UNII: 3OWL53L36A)
- SODIUM CITRATE (UNII: 1Q73Q2JULR)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for Zoledronic Acid?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 351114 - zoledronic acid 4 MG in 5 ML Injection
- RxCUI: 351114 - 5 ML zoledronic acid 0.8 MG/ML Injection
- RxCUI: 351114 - zoledronic acid 4 MG per 5 ML Injection
Which are the Pharmacologic Classes for Zoledronic Acid?
A pharmacologic class is a group of drugs that share the same scientifically documented properties. The following is a list of the reported pharmacologic class(es) corresponding to the active ingredients of this product.
* Please review the disclaimer below.
Zoledronic Acid Injection
Zoledronic acid (Reclast) is used to prevent or treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause ('change of life,' end of regular menstrual periods). Zoledronic acid (Reclast) is also used to treat osteoporosis in men, and to prevent or treat osteoporosis in men and women who are taking glucocorticoids (a type of corticosteroid medication that may cause osteoporosis). Zoledronic acid (Reclast) is also used to treat Paget's disease of bone (a condition in which the bones are soft and weak and may be deformed, painful, or easily broken). Zoledronic acid (Zometa) is used to treat high levels of calcium in the blood that may be caused by certain types of cancer. Zoledronic acid (Zometa) is also used along with cancer chemotherapy to treat bone damage caused by multiple myeloma [cancer that begins in the plasma cells (white blood cells that produce substances needed to fight infection)] or by cancer that began in another part of the body but has spread to the bones. Zoledronic acid (Zometa) is not cancer chemotherapy, and it will not slow or stop the spread of cancer. However, it can be used to treat bone disease in patients who have cancer. Zoledronic acid is in a class of medications called bisphosphonates. It works by slowing bone breakdown, increasing bone density (thickness), and decreasing the amount of calcium released from the bones into the blood.
* Please review the disclaimer below.
We have moved the product label and warning information to a dedicated page, please follow the link below:View Product Label